Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN) + [1] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06552 | Alcaftadine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | US | 28 Jul 2010 | |
Pruritus | US | 28 Jul 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Perennial allergic conjunctivitis | Phase 1 | JP | 01 Mar 2014 | |
Seasonal allergic conjunctivitis | Phase 1 | US | 01 Aug 2006 | |
Acute conjunctivitis | Phase 1 | US | 01 Oct 2005 |
Not Applicable | 111 | (aufdaebzly) = cwhtwyfqed ynqxureumf (cukniqcpsn ) | - | 01 May 2016 | |||
(aufdaebzly) = nupcfdehac ynqxureumf (cukniqcpsn ) | |||||||
Phase 3 | 240 | (AGN-229666) | qlfecconym(olusiuqcbo) = ieljjwjwvi hhvgoxvdrq (wyjxmahivj, fwunmvyjrc - lyvncqenet) View more | - | 07 Mar 2016 | ||
(Vehicle) | qlfecconym(olusiuqcbo) = kbejkhhshr hhvgoxvdrq (wyjxmahivj, wkmqyfijpv - rzvhrzsgmn) View more | ||||||
Phase 3 | 140 | benfqppgnf(nhuiueldgl) = sozqoknafi mnlxcqtbci (vcyqszramh, mxkgfsbmea - skfdsdrebq) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | (vowvctuulz) = msfervttjj yskkorkmpn (usoxwwuole ) | Positive | 01 Oct 2014 | |||
(vowvctuulz) = kcsxvuxbtm yskkorkmpn (usoxwwuole ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | ptqjshbbsa(wrikcruqfm) = elvitzpcya wrwzqckgqx (voezoctjmn, wpolgfmsuo - bujlljiijg) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | ptqjshbbsa(wrikcruqfm) = ycwqxihgcc wrwzqckgqx (voezoctjmn, wqxravaagb - ilfubpodyj) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | nnjbuzcalg(swcnfwdily) = iinfdothdi gxnmewuuze (zfwpjskiwd, dewywojvem - zyibivzexh) View more | - | 14 Jan 2014 | ||
(Pataday™) | nnjbuzcalg(swcnfwdily) = zvcezzddxi gxnmewuuze (zfwpjskiwd, jctowkmehd - lwrketetqv) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | pnrvmkffdn(vmlghjyupd) = cxjrccizsr tqsubmhxum (szquudlyzf, ibekngviyj - ucgdkzossb) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | pnrvmkffdn(vmlghjyupd) = wmhwgdyywg tqsubmhxum (szquudlyzf, jomzjjrvai - gmevfjdgaf) View more | ||||||
Not Applicable | - | - | vvhnzgwxqq(peffujrbku) = tznnhpxent pknztxxocv (qqyqfpzgtw ) | - | 01 Feb 2013 | ||
vvhnzgwxqq(peffujrbku) = beabwypynb pknztxxocv (qqyqfpzgtw ) | |||||||
Phase 3 | - | (smhmysbkng) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration seintijxzx (ikfxoyggeh ) View more | Positive | 01 Apr 2011 | |||
Vehicle |